April 2010
Volume 51, Issue 13
Free
ARVO Annual Meeting Abstract  |   April 2010
Serum Levels of the Phosphorylated Neurofilament Heavy Chain Biomarker of Axonal Injury is Reduced 5 Years After Treatment by Intravenous Methylprednisolone in the Optic Neuritis Treatment Trial
Author Affiliations & Notes
  • J. Pasol
    Ophthalmology,
    Bascom Palmer Eye Institute, Miami, Florida
  • W. J. Feuer
    Biostatistics,
    Bascom Palmer Eye Institute, Miami, Florida
  • J. Guy
    Bascom Palmer Eye Institute, University of Miami, Miami, Florida
  • G. Shaw
    Neuroscience, University of Florida, Gainesville, Florida
  • Footnotes
    Commercial Relationships  J. Pasol, None; W.J. Feuer, None; J. Guy, None; G. Shaw, None.
  • Footnotes
    Support  R01 EY07982
Investigative Ophthalmology & Visual Science April 2010, Vol.51, 636. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      J. Pasol, W. J. Feuer, J. Guy, G. Shaw; Serum Levels of the Phosphorylated Neurofilament Heavy Chain Biomarker of Axonal Injury is Reduced 5 Years After Treatment by Intravenous Methylprednisolone in the Optic Neuritis Treatment Trial. Invest. Ophthalmol. Vis. Sci. 2010;51(13):636.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : To assess axonal loss in patients entered into the optic neuritis treatment trial (ONTT).

Methods: : The Optic Neuritis Treatment Trial randomized 389 patients with acute optic neuritis to intravenous methylprednisolone (IVMP), oral prednisone or placebo treatment arms. We measured serum pNF-H levels in 175 ONTT patients. 63 patients received IVMP, 63 patients received prednisone and 49 patients received placebo. Venous blood was drawn 5 years after enrollment. Optical coherence tomography (OCT) was performed 10 years later.

Results: : Post-hoc least significant difference tests revealed lower pNF-H with IVMP relative to placebo (difference = -0.067; p = 0.047) or prednisone (difference = -0.073, p= 0.021). There was no difference (p = 0.75) between cases with or without MS at 5 years. A subset of 51 patients had retinal nerve fiber layer (RNFL) measurements at year 15 that constituted another outcome variable. There was no significant difference of mean IVMP RNFL=81 µm (n= 18), 78 µm with prednisone (n=18) or 71 mm placebo (n=15). In the subset with RNFL measurements of affected and non-affected eyes of patients with CDMS (n=20), respectively 69 mm and 82 mm, were significantly different (respectively p=0.018 and p=0.001) from those without CDMS, respectively 83 µm and 99 µm (n=31). There was no correlation of the number of T2W MRI brain lesions to pNF-H levels. We found no statistical correlation of pNF-H levels to recovery of visual acuity at 6 months or RNFL thickness at 15 years in patients with or without MS.

Conclusions: : We conclude that IVMP had a small but measurable effect on suppressing neurodegeneration in optic neuritis.

Keywords: neuropeptides • optic nerve • neuro-ophthalmology: optic nerve 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×